Monte Rosa Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 10.87 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 927.36M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1α, IL-1β and IL...